Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Narcolepsy-Pipeline Review, H1 2015

Narcolepsy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Narcolepsy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Narcolepsy-Pipeline Review, H1 2015', provides an overview of the Narcolepsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Narcolepsy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Narcolepsy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Narcolepsy Overview 7

Therapeutics Development 8

Pipeline Products for Narcolepsy-Overview 8

Pipeline Products for Narcolepsy-Comparative Analysis 9

Narcolepsy-Therapeutics under Development by Companies 10

Narcolepsy-Therapeutics under Investigation by Universities/Institutes 11

Narcolepsy-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Narcolepsy-Products under Development by Companies 15

Narcolepsy-Products under Investigation by Universities/Institutes 16

Narcolepsy-Companies Involved in Therapeutics Development 17

Bioprojet SCR 17

Evotec AG 18

Flamel Technologies S.A. 19

Grupo Ferrer Internacional, S.A. 20

Jazz Pharmaceuticals plc 21

SK Biopharmaceuticals Co., Ltd. 22

Taisho Pharmaceutical Co., Ltd. 23

Narcolepsy-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 30

Drug Profiles 31

arbaclofen-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs to Agonize Orexin Receptor for Narcolepsy-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

EVT-501-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

JZP-386-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

pitolisant-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

SKL-N05-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Agonize Orexin Receptor for Narcolepsy and EDS-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

sodium oxybate-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

sodium oxybate-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

THN-102-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

TS-091-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Narcolepsy-Recent Pipeline Updates 46

Narcolepsy-Dormant Projects 49

Narcolepsy-Discontinued Products 50

Narcolepsy-Product Development Milestones 51

Featured News & Press Releases 51

May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 51

Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 51

Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 52

Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 52

Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 53

Jun 02, 2014: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 53

May 27, 2014: Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting 54

May 07, 2014: Sleep Researchers at SRI International Identify Promising New Treatment for Narcolepsy 54

Apr 07, 2014: Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate 55

Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Number of Products under Development for Narcolepsy, H1 2015 8

Number of Products under Development for Narcolepsy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Narcolepsy-Pipeline by Bioprojet SCR, H1 2015 17

Narcolepsy-Pipeline by Evotec AG, H1 2015 18

Narcolepsy-Pipeline by Flamel Technologies S.A., H1 2015 19

Narcolepsy-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 20

Narcolepsy-Pipeline by Jazz Pharmaceuticals plc, H1 2015 21

Narcolepsy-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 22

Narcolepsy-Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 30

Narcolepsy Therapeutics-Recent Pipeline Updates, H1 2015 46

Narcolepsy-Dormant Projects, H1 2015 49

Narcolepsy-Discontinued Products, H1 2015 50

List of Figures

Number of Products under Development for Narcolepsy, H1 2015 8

Number of Products under Development for Narcolepsy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bioprojet SCR

Evotec AG

Flamel Technologies S.A.

Grupo Ferrer Internacional, S.A.

Jazz Pharmaceuticals plc

SK Biopharmaceuticals Co., Ltd.

Taisho Pharmaceutical Co., Ltd.

Narcolepsy Therapeutic Products under Development, Key Players in Narcolepsy Therapeutics, Narcolepsy Pipeline Overview, Narcolepsy Pipeline, Narcolepsy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com